HMS1005 vs PB-201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
HMS1005
Developed by Hua Medicine
NCT06498284 · Phase 1 · completed
The trial randomized participants against a matched placebo with both participants and investigators blinded, but the primary measures were safety and drug levels rather than a validated diabetes outcome like HbA1c. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, drug code, country, design and enrollment.
Reported efficacy
Incidence of adverse events (11 Days); Area under the plasma concentration versus time curve (AUC) (72 hour); maximum observed concentration (Cmax) (72 hours); time of the maximum observed concentration (Tmax) (72 hours); apparent terminal elimination half life (t1/2) (72 hours): US Phase Ia single ascending dose study, 40 T2D subjects: HM-002-1005 near-completely converts to HMS5552 (dorzagliatin) in vivo; prolonged half-life vs dorzagliatin; Cmax at 184.5mg single dose comparable to 75mg single dose of dorzagliatin
Result source: NCT06498284
PB-201
Developed by PegBio and partners
NCT05102149 · Phase 3 · status unknown
This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HMS1005 | PB-201 |
|---|---|---|
| HbA1c, change | —Not reported | —Not reported |
| Body weight, change (kg) | —Not reported | —Not reported |
| HbA1c below 7% | —Not reported | —Not reported |
| Fasting plasma glucose, change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- HMS1005
- —Not reported
- PB-201
- —Not reported
Body weight, change (kg)
- HMS1005
- —Not reported
- PB-201
- —Not reported
HbA1c below 7%
- HMS1005
- —Not reported
- PB-201
- —Not reported
Fasting plasma glucose, change
- HMS1005
- —Not reported
- PB-201
- —Not reported
3-point MACE (% with event)
- HMS1005
- —Not reported
- PB-201
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HMS1005: no structured comparison results are available for Type 2 Diabetes.
PB-201: no structured comparison results are available for Type 2 Diabetes.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HMS1005's landscape · PB-201's landscape